{
  "ticker": "AGIO",
  "company_name": "Agios Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07075640",
      "title": "A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2025-07-07",
      "completion_date": "2026-01-13",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT06745271",
      "title": "A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Participants",
      "start_date": "2024-12-20",
      "completion_date": "2025-02-21",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04995315",
      "title": "Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Pyruvate Kinase Deficiency",
      "start_date": "2021-07-02",
      "completion_date": "2023-09-22",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03991312",
      "title": "Study to Evaluate the Effect of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of Mitapivat Sulfate (AG-348) in Healthy Adult Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2019-06-20",
      "completion_date": "2019-09-10",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04902833",
      "title": "Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "",
      "condition": "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia",
      "start_date": "2022-02-01",
      "completion_date": "2026-12-31",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT03960502",
      "title": "A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Male Participants",
      "start_date": "2019-05-16",
      "completion_date": "2019-09-07",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05490446",
      "title": "A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2",
      "condition": "Myelodysplastic Syndromes",
      "start_date": "2022-11-07",
      "completion_date": "2029-03",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03250598",
      "title": "Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy, Japanese, Non-Asian",
      "start_date": "2017-08-09",
      "completion_date": "2017-10-09",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03071770",
      "title": "Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2017-03-31",
      "completion_date": "2017-09-06",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03282513",
      "title": "A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Hepatic Impairment",
      "start_date": "2017-09-26",
      "completion_date": "2018-03-31",
      "enrollment": 0,
      "sponsor": "Agios Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE1": 26,
      "": 5,
      "PHASE2": 8,
      "PHASE4": 1,
      "PHASE3": 7,
      "EARLY_PHASE1": 1,
      "PHASE1, PHASE2": 1,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "RECRUITING": 3,
      "COMPLETED": 32,
      "ACTIVE_NOT_RECRUITING": 10,
      "ENROLLING_BY_INVITATION": 1,
      "TERMINATED": 3,
      "NOT_YET_RECRUITING": 1
    },
    "active_trials": 14,
    "completed_trials": 32,
    "conditions": [
      "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies",
      "Advanced Solid Tumor, IDH1 Mutation, Glioma",
      "Anemia",
      "Chondrosarcoma, Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, IDH1 Gene Mutation",
      "Healthy",
      "Healthy Male Participants",
      "Healthy Participants",
      "Healthy Volunteer",
      "Healthy Volunteers",
      "Healthy Volunteers, Anemia, Sickle Cell",
      "Healthy, Japanese, Non-Asian",
      "Hematologic Neoplasms",
      "Hepatic Impairment",
      "IDH1 Mutation Myeloid Neoplasms",
      "Lymphoma",
      "Moderate Hepatic Impairment",
      "Myelodysplastic Syndromes",
      "Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia",
      "Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia",
      "Pyruvate Kinase Deficiency",
      "Pyruvate Kinase Deficiency, Anemia, Hemolytic",
      "Pyruvate Kinase Deficiency, Congenital Non-Spherocytic Hemolytic Anemia",
      "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Anemia, Anemia, Hemolytic",
      "Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia",
      "Sickle Cell Disease",
      "Sickle Cell Disease, Nephropathy",
      "Thalassemia",
      "Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:07.283811",
    "search_query": "Agios Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Agios+Pharmaceuticals,+Inc."
  }
}